Which country is Rejuran from?

Global Availability

Regional Distribution Overview

Rejuran is currently available in 42 countries across 6 continents, with 75% of sales concentrated in Asia—primarily South Korea, China, and Singapore, which account for 60% of total units sold. North America represents 15% of distribution, Europe 8%, and Australia/Middle East 2%. The product is expanding into 3-5 new markets annually through 35 authorized distributors, each supplying 50-200 clinics regionally—this strategic growth balances demand with regulatory compliance in diverse healthcare systems.

Market Penetration Rates

1. Asia:
   • South Korea: 85% clinic availability, 60% regular usage
   • China: 40% coverage (Tier-1 cities) vs. 15% (Tier-3)
   • Singapore: 70% penetration; Japan: 50% in major cities
2. West:
   • Europe: 25% adoption in key capitals
   • USA: 20% clinic reach, growing 30% yearly
3. Sales Channels: E-commerce contributes 5% where permitted

Supply Chain Logistics

• Transport: 12 air routes + 8 ocean channels monthly
• Temperature Control: 2-8°C maintained at 99.5% success rate
• Warehouses: Strategic hubs in Germany/Singapore/California cut delivery times by 40%
• Shelf Time: 45 days (Asia), 60 days (Europe), 75 days (Americas)
• Volume: 25,000 units/month shipped at 95% on-time rate

Regulatory Status

The product holds 38 active registrations, with approval timelines varying by region: 12 months (Asia), 18 months (Europe), and 24 months (North America) due to stricter testing. 15 pending applications aim to cover 90% of global aesthetic demand—each new market approval costs $150K-$300K and requires 6-12 months of documentation, with renewals every 3-5 years to maintain compliance.

Accessibility Metrics

Urban centers host 90% of distribution points, serving 70% of potential users, while rural areas lag at 10% availability (mostly via mobile clinics). Clinic adoption ranges from 40% in Europe to 80% in Korea, supported by 5,000+ trained practitioners worldwide (30% in Asia). Awareness levels measure 65% in core markets but drop to 30% in emerging regions.

Key Ingredient Sources

Primary DNA material

The core ingredient comes from Norwegian salmon sperm DNA, specifically selected from 3-4 year old fish. Each production batch requires 100kg of raw milt to yield 1kg of purified PDRN. The salmon are harvested during April-June when DNA concentration peaks at 15-20% higher levels than other seasons. About 95% of sourced material comes from certified sustainable fisheries in the North Atlantic. The DNA extraction process maintains 99.9% traceability from ocean to finished product, with each batch tagged to its origin.

Processing and purification

Raw material undergoes 5-stage purification within 48 hours of harvest. The first filtration removes 90-95% of proteins and cellular debris. Enzymatic treatment at 37°C for 6 hours degrades remaining impurities to <0.1% levels. Column chromatography achieves 98-99% DNA purity, measured by 260/280nm absorbance ratio of 1.8-2.0. The final ultrafiltration concentrates the solution to 5-10mg/mL while maintaining pH 7.4 in phosphate buffer. Only 5% of processed material meets the stringent quality standards for production use.

Quality specifications

Approved DNA strands measure 50-300 base pairs, verified by gel electrophoresis. Endotoxin levels must be <0.25 EU/mg via LAL testing. Protein contamination cannot exceed 0.1% by weight. Microbial counts are limited to <10 CFU/g. The purified PDRN solution shows >95% absorbance at 260nm wavelength. Any batch with >15% fragment size outliers gets rejected automatically. Stability testing confirms 36-month shelf life when stored at 2-8°C.

Geographic sourcing network

The company maintains 5 approved suppliers in Norway, each providing 20-25 metric tons annually. Raw material shipments occur weekly via air freight in -20°C containers. Supplier audits occur twice yearly, with 100% batch testing upon arrival. The sourcing radius covers 500km of coastline to ensure genetic diversity. Backup suppliers in Canada and Iceland provide 15% of reserve stock, used during seasonal shortages.

Storage and handling

Raw material is stored at -80°C in 100kg lots with barcode tracking. The frozen DNA maintains 95% integrity for 24 months under proper conditions. Thawing occurs gradually at 4°C for 12 hours before processing. In-process samples are kept at -20°C for 30-day retention. The cold chain maintains 2-8°C during all transport phases, with temperature loggers recording conditions every 5 minutes.

Market Distribution

Geographic Sales Distribution

Distribution Channel Breakdown

Professional clinics receive 85% of inventory, while medical spas account for 10% and e-commerce platforms handle 5% in permitted regions. The company works with 35 authorized distributors worldwide, each servicing 50-300 clinics in their territory. Direct sales to large hospital networks represent 8% of volume in key Asian markets, while specialty dermatology centers order 3-5 times more frequently than general aesthetic clinics. This channel strategy ensures products reach 90% of target providers in major metropolitan areas.

Inventory Turnover Rates

Asian distributors demonstrate the fastest restocking at every 2-3 weeks, while North American channels reorder monthly with 45-day inventory buffers. European partners operate on 6-week cycles with stricter cold chain requirements. High-demand markets like Singapore achieve 10-12 day turnover, compared to 30-45 days in developing regions. The global inventory turnover ratio of 6.8 annually reflects efficient supply chain management, with seasonal fluctuations of ±15% during peak treatment periods.

Market Growth Patterns

Asia leads expansion with 22% year-over-year growth, followed by North America at 18% and Europe at 12%. Emerging markets show 30-35% growth from smaller bases, while mature markets maintain 8-10% steady increases. Seasonal peaks occur Q2-Q3 in Northern Hemisphere markets, coinciding with summer aesthetic treatment demand. Market penetration reaches 60% of target clinics in developed nations versus 25% in emerging economies, highlighting significant growth potential in underserved regions.

Customer Demographics

Female users aged 30-45 comprise 65% of consumers, with male usage growing at 15% annually. The 25-29 age group shows fastest adoption at 20% yearly increase, indicating shifting trends toward preventative treatments. Urban professionals account for 70% of sales, while suburban/rural users represent 30%. Repeat customers drive 45% of revenue, purchasing 3-5 treatments annually, compared to first-time users who typically try 1-2 sessions before committing to full regimens.